Group items tagged

The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation. Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships. Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook. Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.

Talk of hub and spoke models has been rumbling on for as long as I can remember. The topic has once again hit the headlines as the government announced a fresh consultation for its proposed changes, calling on all interested parties to submit their views by 8th June. The argument for hub and spoke is to allow independents to have the same level playing field as the larger groups who have been operating this model for some time. The government also sees significant efficiency gains in centralisation, arguing this will free pharmacists time away from dispensing to focus on clinical services. The latest consultation advocates two models being created. In the first model, the dispensed medication is sent back to the spoke. In the second model, the completed medication can be sent out directly to the patient. The latter is a new concept which could open up new opportunities in how services are delivered. Pharmacies could effectively outsource the entire dispensing and delivery to housebound patients and care homes allowing pharmacies to take on new business without having to worry about logistics and geography.

The Pharmaceutical Services Negotiating Committee announced last week that it is in discussions with the Department of Health and Social Care (DHSC) and NHS England about relieving capacity pressures, such as a relaxation of pharmacy opening hours requirements. PSNC is also scheduling webinars to talk with contactors about the steps they might be willing to take in future, to cut costs, should emergency financial relief fail to materialise. The pharmacy regulator reported that many of its members felt that it was no longer tenable for pharmacies to keep offering all of the free and non-core services to patients that they would like to, and that all contractors should consider what steps they could take to try to safeguard their businesses and their core services for patients. PSNC is also keen to talk to contractors about their current situation and the steps they might be willing to take in future, should emergency relief not be forthcoming.

The National Pharmacy Association (NPA)'s Health Education Foundation (HEF) has funded a major study that aimed to test the SPUR tool and evaluate how effective it was at measuring medicines adherence. The study has been published in the British Medical Journal Open. Dr Joshua Wells, a fourth year PhD candidate at Kingston University, who was awarded the NPA bursary, was the lead researcher for the SPUR UK study, under the guidance of Professor Reem Kayyali. Created by Observia, a health research group, SPUR is a self-assessment questionnaire which helps to detect a patient's risk of medicine non-adherence and aims to accurately articulate the reasons for health behaviour. As well as funding from HEF, the study was made possible via a partnership with Kingston University and Kingston Hospital. HEF chair of Trustees, Dr Ian Cubbin, said: "We are delighted that NPA's Health Education Foundation has played a part in such an important study. This research could lead ultimately to a far more personalised, tailored approach to medicines optimisation - recognising that people's medicines behaviour can be highly individual to them."

The Royal Pharmaceutical Society (RPS) has launched a new campaign to help parents and carers in pharmacy get the support they need in the workplace as part of its inclusion and diversity work. "A lack of flexibility in employment can mean work life balance is hard to keep, ramping up the pressure even more," said RPS. The society wants to lift some of the burdens on parents and carers and challenge barriers to inclusion in the workplace. It'll challenge negative attitudes to parents and carers through a brand new guide to the microaggressions you experience in the workplace. Drop in ABCD meeting at 7pm on 05 October to contribute your ideas. It wants pharmacists to be able to choose flexible working whenever they need it. Join RPS's livestream across all its social media channels at 6.30pm on Weds 26 October to hear from two pharmacists about how to make it happen!

On World Pharmacists' Day, the Council of the Pharmaceutical Society NI (PSNI) thanked pharmacists working in every sector of pharmacy in Northern Ireland (NI) for their continued service to the public. The theme of this year's International Pharmaceutical Federation's World Pharmacists' Day, (25 September 2022) was 'Pharmacy united in action for a healthier world'. In acknowledgement of the day, Dr. Jim Livingstone, president of the Council of the Pharmaceutical Society NI said: "The theme of this year's World Pharmacists' Day, 'Pharmacy united in action for a healthier world' highlights pharmacy's positive impact on health around the world and seeks to further strengthen solidarity amongst the profession. "In Northern Ireland, pharmacy played a prominent role in primary health care throughout the pandemic and remains the public's most trusted and accessible frontline health care profession. "As pharmacy continues to develop additional services for the public and encompasses broader roles for pharmacists than ever before, it is essential, no matter what pharmacy sector pharmacists practise in, that the Pharmaceutical Society NI's Code (Professional standards of conduct, ethics and performance for pharmacists in Northern Ireland) remains at the core of pharmacists' practice. It is through this adherence to the Code, that pharmacy remains a united profession, providing positive health outcomes for patients and maintaining public trust.

Leaders from across the pharmacy sector and trade bodies dwelled on the challenges faced by the pharmacists at the Sigma Conference held on Sunday (2 October). "If the cost of carrying out regulation is higher than the benefits, it's time for all the bodies to sit together and talk on what can be adjusted accordingly," said Salim Jetha, Chairman, Avicenna. Jetha highlighted the challenges faced by the independent pharmacy and also raised the concern about the 'level playing field' for pharmacists compared to GPs. He said: "GPs get paid for energy cost, premises cost, the staffing cost. We don't get paid for that. So don't be misled by saying we are being exactly the same. Yes, on paper we are, but in reality we are not. I think also the rules of engagement are different." He called for better collaboration with GPs, and urged PSNC and other trade bodies to ensure a level playing field. Janet Morrison, CEO, Pharmaceutical Services Negotiating Committee(PSNC), warned that the pressure in the sector is building up to a 'breaking point'.

A new report based on research from pharmacists across England by Sanofi, has called for the introduction of a 'national self-care strategy' to relieve the burden currently faced by health services. The new report, titled 'Driving a self-care revolution in the UK', explores the views of pharmacists, patients and doctors on self-care and the support needed to deliver it more effectively. While self-care policy measures are estimated to increase monetary savings for healthcare systems and national economies by 16%, this report highlights the right tools and resources are not yet in place to enable pharmacists to play a greater role in delivering self-care advice and medicines to patients. "As many as 77% of pharmacists said they would support the creation of a National Self-Care Strategy to provide national leadership on improving understanding of self-care and encourage its use among both patients and clinicians," the report said. According to the report, currently, 33% of pharmacists working for independent or small pharmacy chains do not have the resources to support patients with self-care, alongside their other roles. "To tackle this, close to half (45%) of pharmacists believe greater emphasis by primary care practitioners on the benefits of self-care would leave pharmacists in a better place to support patients. Similarly, 42% believe that training and recruiting more pharmacists would improve their capacity to deliver self-care advice."

The menopause is a natural aging process, whereby a woman's oestrogen level drops thus disrupting periods until they eventually stop. A woman is said to be in the menopause when her periods have stopped for 12 months. The age when this usually occurs is between 45-55 but symptoms can begin prior to this. Symptoms vary and not all women experience them all. They include hot flushes, vaginal dryness, joint and muscle pain, insomnia, reduced libido, urinary problems such as bladder weakness or Urinary Tract Infections (UTIs), but this list is not exhaustive. Up to a third of women declare that the menopause affects their quality of life. It is obvious that such physical changes can have an effect on ones well-being. Women going through the menopause are at increased risk of developing depression, low self-esteem and problems with concentration (often called brain fog). There are lots of misconceptions in the public and workplace around menopause as it is a little discussed topic. Did you know 45 per cent of women feel their menopause symptoms have had a negative impact on their work and 47 per cent of women have said that they won't tell their employer if they need to take a day-off from work because of menopausal symptoms? So, with women making up nearly half of the UKs workforce, have you thought about what support your workplace offers for you? And if you are an employer, what could you be doing to support your colleagues who need help during this time?

The Health Committee's new report has reminded the government of a much-needed pharmacy workforce plan to support recruitment, training, and retention of staff. The report makes a number of recommendations to optimise workloads across primary care, reduce pressure on general practice and hospitals, and support the integrated care systems. It also recognises the potential of pharmacist independent prescribers to support patient care, backed by appropriate supervision, training, and opportunities for professional development. RPS England gave evidence to MPs on the Committee at a public hearing in May, highlighting key issues to support the pharmacy workforce. RPS director for England, Ravi Sharma, said: "Today's report underlines the urgent need for the Government to set out a comprehensive workforce plan for health and care. "It rightly recognises that boosting recruitment and retention, supporting staff wellbeing, fostering inclusion and diversity, and investing in education and training will be crucial to the future of the NHS.

The Competition and Market Authority (CMA) has suggested regulatory levers to curb "potential competition risk" from hub and spoke dispensing. In its response to the hub and spoke dispensing consultation, led by the Department for Health and Social Care (DHSC) last week, the competition watchdog said that a pro-active approach to monitoring the effect of hub and spoke dispensing and subsequent early consideration of any competition concerns was likely to be more effective and potentially less costly than any "ex-post enforcement any ex-post enforcement or unpicking of subsequently embedded competition issues". The competition watchdog has made a few suggestions to identify and remove the barriers to competition that might emerge with the new business models entering the market. It has asked the department to enable a "more level playing field". "Smaller independent pharmacies should, have improved access to automation and new dispensing models," it said.

HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer. The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022. David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of over-the-counter self-care products. He commented: "Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to step away from the business. "I am proud of all that we have accomplished, making HRA well-known for its Women's Health, Wound Care and Scar Care leadership, operating via brands including ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned to elevate this business and these brands to the next level."

he Pharmacy Schools Council (PhSC) has elected Professor Katie Maddock as the organisation's new chair. Prior to becoming head of school at Keele University, Professor Maddock had been MPharm course director and associate dean for education for the Faculty of Medicine and Health Sciences, responsible for developing the clinical teaching at Keele. Before joining Keele University, she taught clinical pharmacy and pharmacy practice at Aston University. Her research interests lie in pharmacy education, particularly the use of technology in teaching, clinical therapeutics, augmented reality simulation and interprofessional education. She was also awarded a principal fellowship of the Higher Education Academy in November 2020. Having worked in hospital pharmacy, Professor Maddock is acutely aware of the pressures that Covid-19 has placed on healthcare, as well as the importance of retaining and building upon the positive changes to patient care and pharmacy practice that were developed in response to the pandemic.

The Royal Pharmaceutical Society (RPS) has confirmed it will respond to UK Commission's 'call for evidence' on pharmacy professional leadership. The commission wants to ensure the professions are well equipped, with a voice to help shape the future, and enabled to develop through sharing and learning from best practice. The UK Commission on Pharmacy Professional Leadership has been set up by the chief pharmaceutical officers of England, Scotland, Wales and Northern Ireland. It will produce recommendations for the future of pharmacy professional leadership in the UK. The commission is co-chaired by Nigel Clarke, former chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, professor of medical education at University College London's Medical School. The commission will be hosting a webinar and has urged the associations and individuals to take part in 'call for evidence' which has been launched to inform and develop its work. A webinar in England will take place on Wednesday 7 September 6:30 - 8 pm. In Scotland it will be organised on Tuesday 6 September 7-8:30 pm and in Wales it will be hosted on Thursday 8 September 7-8:30 pm.

The Pharmaceutical Defence Association (PDA) has urged health ministers of the UK to take a strict and necessary action against the unnecessary closures of pharmacy. Concerned over the rising number of pharmacy closures, PDA has written an open letter to health secretary Steve Barclay; Robin Swann, health minister for Northern Ireland; Eluned Morgan, minister of health and social services for Wales; and Humza Yousaf, the Scottish health secretary. In its letter, PDA said: "The minister of health must now ensure the regulation of poor business behaviours and be prepared to take over rogue pharmacies, however large their corporate owner may be. If patients' access to NHS services is to be protected from the consequences of avoidable full or part-day pharmacy closures." The association believes it is only a matter of time before serious harm to patients' health will be caused by the decisions of mainly large chains of pharmacies to close some of their branches for all or part of a day, instead of engaging an available pharmacist to cover their agreed opening hours. "While a small number of unforeseen closures have always occurred from time to time in pharmacies for genuine reasons, the indiscriminate scale at which closures have now become commonplace seems to have evolved over the last 20 months."

The Association of Independent Multiple Pharmacies (AIMp) and senior official of NHS Property Services (NHSPS) had a meeting on August 18 to review the rent policy for health centre pharmacies. Earlier, the association had sent a letter to NHSPS that was signed by pharmacies from across the sector, including single independents, pharmacy groups and members of the Company Chemists' Association. The letter outlined concerns about rent reviews and the impact of it on the co-located health centre pharmacies. Dr Leyla Hannbeck, CEO of AIMp, said: "We outlined that whilst in the past, the norm established by the industry, was to base rents for co-located pharmacies primarily based on patient list size, (and taking account of a few other factors), the industry now needs to revise the basis on which rents are determined for co-located pharmacies." The association, on behalf of the pharmacy sector, met the CEO of NHSPS and two of their senior directors (director or property management and their finance director).

Essential Pharma, an international speciality pharma group, has procured an establishment and manufacturing licences in Switzerland and Malta. Following a successful inspection by Swissmedic, the company has been granted an establishment licence in Switzerland, which will allow the company to significantly enhance its supply chain efficiency for a wide range of important medicinal products. It will apply to transactions for both finished and unfinished pharmaceuticals, allowing importing, exporting, wholesaling and trading abroad. Essential Pharma has also received a manufacturing and importation authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection by the Malta Medicines Authority. The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater flexibility in how the business manages the flow of medicines across its territories. These approvals strengthen the company's geographical expansion, improve its operational efficiencies, and enhance its offering as a global business partner. They will also provide new strategic opportunities for the company and will play a fundamental role in driving value creation through functional improvements to scale and productivity.

The Conservative Party Prime Ministerial candidate Rishi Sunak visited Bassett Pharmacy in Southampton on Wednesday (Aug 24) - the pharmacy that used to be run by his family. During the visit, Sunak is reported to have said that he intends to reform the NHS and achieve value for money from health spending, should he become prime minister. Giving his reaction to the visit, National Pharmacy Association (NPA) chief executive Mark Lyonette said: "If Rishi Sunak is serious about NHS reform, he would do well to start with a 'pharmacy first' approach to prevention and treatment which has the potential to transform the way people access NHS care. "That can only happen with a sustained increase in funding for our sector, which is facing much harder times now than it ever did when Mr Sunak's parents owned a pharmacy years ago." Earlier in the week, NPA board member Hiten Patel met the former chancellor when he visited West Harrow for a campaign event on August 23. Patel took the opportunity to explain that pharmacies in England are not being properly supported to fulfil their potential within the NHS.

The Royal Pharmaceutical Society (RPS) has called pharmacy employers and pharmacy trade unions to come together to a round table meeting to agree on principles for a way forward that ensures patients benefit consistently from access to high quality, adequately staffed, safe pharmacy services. It has also urged the governments, NHS organisations and individual pharmacy teams to define clear prioritisation plans, which can be embedded in organisational business continuity plans which set out the pharmacy services that are essential and must always be provided and can be de-prioritised at specific levels of pressures. The challenges for pharmacies are compounded by the escalating cost of living crisis. With unprecedented levels of burnout among pharmacists, pharmacy closures and the potential for strike action, RPS has called for three things- 'professionalism, respect and prioritisation.'

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.